Myriad Genetics secures multi-year UnitedHealthcare contract renewal through 2027

MYRIAD GENETICS INC

New agreement covers tests: MyRisk, MyChoice CDx, BRACAnalysis CDx, Foresight, Prequel, GeneSight, Prolaris.
Contract effective Jan 1, 2024 to Dec 31, 2027; specific pricing terms not disclosed.
Company reiterates long-term financial targets announced at Sep 19, 2023 investor day, consistent with this renewal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.